Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: Data from the French registry REGATE - Archive ouverte HAL Access content directly
Journal Articles Joint Bone Spine Year : 2018

Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: Data from the French registry REGATE

Abstract

Objectives Assess the frequency of paradoxical reactions encountered in daily practice under tocilizumab, using the REGATE (Registry-RoActemra) registry. The secondary objectives were to determine the type of paradoxical reaction and the consequences of these reactions. Methods The REGATE registry is an independent prospective registry, promoted by the French Society of Rheumatology, consisting of patients treated with tocilizumab for rheumatoid arthritis. The paradoxical reaction was retained if it was a paradoxical precipitation of a condition for which tocilizumab was indicated, if tocilizumab was being used for an alternative indication, and if it appeared after at least one tocilizumab infusion. Results Among the 1491 patients included with at least one follow-up visit (3429 patient-years), a paradoxical reaction occurred in 9 patients (0.60% of patients; 2.62/1000 patient-years). These were 7 de novo pathologies (3 vasculitis, 3 uveitis, 1 lupus) and 2 exacerbations of pre-existing conditions (1 vasculitis, 1 lupus). Permanent discontinuation of tocilizumab was chosen for 5 patients. Conclusions In the REGATE registry, the occurrence of paradoxical reactions in patients treated with tocilizumab was rare.
Not file

Dates and versions

hal-02190639 , version 1 (22-07-2019)

Identifiers

Cite

William Terreaux, Claire Masson, Jean-Paul Eschard, Thomas Bardin, Arnaud Constantin, et al.. Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: Data from the French registry REGATE. Joint Bone Spine, 2018, 85 (1), pp.53-57. ⟨10.1016/j.jbspin.2017.01.002⟩. ⟨hal-02190639⟩
46 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More